Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Keratosis, Actinic 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Warts 1Squamous Intraepithelial Lesions 1Skin Neoplasms 1Radiodermatitis 1Parapsoriasis 1Non-Melanoma Skin Cancer (NMSC) 1Neoplasms 1Hypogonadism 1Hemangioma, Cavernous 1Hemangioma 1Head and Neck Cancer Patients Treated With Radiotherapy 1Fatigue 1Exanthema 1Eunuchism 1Dermatitis, Contact 1Carcinoma, Squamous Cell 1Carcinoma, Basal Cell 1Carcinoma 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Cyclophosphamide 361Trastuzumab 352Paclitaxel 304Docetaxel 272Capecitabine 222Letrozole 221Carboplatin 185Doxorubicin 181Tamoxifen 157Radiotherapy 154Epirubicin 145Fulvestrant 143Anastrozole 139Surveys and Questionnaires 133Exercise 128pertuzumab 113Vinorelbine 110Blood Specimen Collection 109exemestane 106palbociclib 104Bevacizumab 104pembrolizumab 98Magnetic Resonance Spectroscopy 97Albumin-Bound Paclitaxel 87Gemcitabine 84Drug Therapy 83Lapatinib 78130-nm albumin-bound paclitaxel 72Neoadjuvant Therapy 71Cisplatin 69

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Breast Neoplasms × Gels × Clear all
NCT04570956 2026-01-23

Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk

Mayo Clinic

Phase 2 Terminated
65 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡